Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Judy, Mak"'
Autor:
WeiYu Lin, Daqi Xu, Cary D. Austin, Patrick Caplazi, Kate Senger, Yonglian Sun, Surinder Jeet, Judy Young, Donnie Delarosa, Eric Suto, Zhiyu Huang, Juan Zhang, Donghong Yan, Cesar Corzo, Kai Barck, Sharmila Rajan, Carrie Looney, Vineela Gandham, Justin Lesch, Wei-Ching Liang, Elaine Mai, Hai Ngu, Navneet Ratti, Yongmei Chen, Dinah Misner, Tori Lin, Dimitry Danilenko, Paula Katavolos, Estelle Doudemont, Hirdesh Uppal, Jeffrey Eastham, Judy Mak, Patricia E. de Almeida, Katherine Bao, Azadeh Hadadianpour, Mary Keir, Richard A. D. Carano, Lauri Diehl, Min Xu, Yan Wu, Robby M. Weimer, Jason DeVoss, Wyne P. Lee, Mercedesz Balazs, Kevin Walsh, Kathila R. Alatsis, Flavius Martin, Ali A. Zarrin
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Colony-stimulating factor 1 (CSF1) and interleukin 34 (IL34) signal via the CSF1 receptor to regulate macrophage differentiation. Studies in IL34- or CSF1-deficient mice have revealed that IL34 function is limited to the central nervous system and sk
Externí odkaz:
https://doaj.org/article/f5bbd900f7f94b86b15fbd853c8ad352
Autor:
Kevin B. Walsh, Jeong M. Kim, Jovencio Borneo, Vincent Javinal, Aurelie Herault, Rajiv Jesudason, Genevive Hernandez, Judy Mak, Patricia E. de Almeida
Antiangiogenic therapies that target the VEGF pathway have been used clinically to combat cancer for over a decade. Beyond having a direct impact on blood vessel development and tumor perfusion, accumulating evidence indicates that these agents also
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::235e4e725cc5aa297c65f359b53e0f02
https://doi.org/10.1158/2326-6066.c.6550410
https://doi.org/10.1158/2326-6066.c.6550410
Autor:
Kevin B. Walsh, Jeong M. Kim, Jovencio Borneo, Vincent Javinal, Aurelie Herault, Rajiv Jesudason, Genevive Hernandez, Judy Mak, Patricia E. de Almeida
Supplementary tables 1-4 and supplementary figures 1-8.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95c71a4032796d19e9a2c56f6d9a9408
https://doi.org/10.1158/2326-6066.22543803.v1
https://doi.org/10.1158/2326-6066.22543803.v1
Autor:
Teemu T. Junttila, Kevin B. Walsh, Melissa R. Junttila, Klara Totpal, James Ziai, Alfonso Arrazate, Patricia De Almeida, Aurelie Herault, Judy Mak, Ryan Ybarra, Ji Li
Purpose:The response to cancer immune therapy is dependent on endogenous tumor-reactive T cells. To bypass this requirement, CD3-bispecific antibodies have been developed to induce a polyclonal T-cell response against the tumor. Anti-HER2/CD3 T-cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::714e2af02a06f65fb3c5f2f456132a1b
https://doi.org/10.1158/1078-0432.c.6527412.v1
https://doi.org/10.1158/1078-0432.c.6527412.v1
Autor:
Teemu T. Junttila, Kevin B. Walsh, Melissa R. Junttila, Klara Totpal, James Ziai, Alfonso Arrazate, Patricia De Almeida, Aurelie Herault, Judy Mak, Ryan Ybarra, Ji Li
Fig. S1. Subset analysis of tumor infiltrating and splenic CD8+ T cells after treatment with anti-HER2/CD3 TDB; Fig. S2. Anti-HER2/CD3 TDB increases intra-tumoral lymphocyte infiltration in Fo5 allograft model of HER2 overexpressing breast cancer wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::551368a9430de27f25df5a0aac223ce1
https://doi.org/10.1158/1078-0432.22470009
https://doi.org/10.1158/1078-0432.22470009
Autor:
Kevin Walsh, Aurelie Herault, Genevive Hernandez, Patrícia de Almeida, Judy Mak, Jeong M. Kim, Rajiv Jesudason, Vincent Javinal, Jovencio Borneo
Publikováno v:
Cancer Immunology Research. 8:806-818
Antiangiogenic therapies that target the VEGF pathway have been used clinically to combat cancer for over a decade. Beyond having a direct impact on blood vessel development and tumor perfusion, accumulating evidence indicates that these agents also
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9bc6b07a7032555f678c5771e7435df3
https://doi.org/10.1158/2326-6066.cir-19-0360
https://doi.org/10.1158/2326-6066.cir-19-0360
Autor:
Hsiang Ling Chen, Li An, Yu Hsin Tsai, Judy Mak, Shuang Yang, Lei Shi, Douglas A. Stow, Rebecca L. Lewison, Weihua Xu
Publikováno v:
Journal of Artificial Societies and Social Simulation. 23
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f5a2274a88128e704c6d6226cdac636
https://doi.org/10.18564/jasss.4196
https://doi.org/10.18564/jasss.4196
Autor:
Sharmila Rajan, Eric Suto, Judy Young, Kevin Walsh, Wyne P. Lee, Yongmei Chen, Elaine Mai, Dinah Misner, Kate Senger, Dimitry M. Danilenko, Navneet Ratti, Ali A. Zarrin, Mary E. Keir, Patrícia de Almeida, Justin Lesch, Judy Mak, Kai H. Barck, Cary D. Austin, Cesar A. Corzo, Zhiyu Huang, Flavius Martin, Carrie Looney, Hirdesh Uppal, Hai Ngu, Yonglian Sun, Vineela D. Gandham, Wei-Ching Liang, Lauri Diehl, Surinder Jeet, Estelle Doudemont, Tori Lin, Jason DeVoss, Jeffrey Eastham, Wei Yu Lin, Azadeh Hadadianpour, Kathila R. Alatsis, Donnie Delarosa, Paula Katavolos, Juan Zhang, Katherine Bao, Richard A.D. Carano, Patrick Caplazi, Min Xu, Yan Wu, Robby M. Weimer, Mercedesz Balazs, Donghong Yan, Daqi Xu
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 10 (2019)
Frontiers in Immunology, Vol 10 (2019)
Colony-stimulating factor 1 (CSF1) and interleukin 34 (IL34) signal via the CSF1 receptor to regulate macrophage differentiation. Studies in IL34- or CSF1-deficient mice have revealed that IL34 function is limited to the central nervous system and sk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fac9dee7283906729daedd8a3091d3c
https://doi.org/10.3389/fimmu.2019.02019
https://doi.org/10.3389/fimmu.2019.02019
Autor:
Patricia E, de Almeida, Judy, Mak, Genevive, Hernandez, Rajiv, Jesudason, Aurelie, Herault, Vincent, Javinal, Jovencio, Borneo, Jeong M, Kim, Kevin B, Walsh
Publikováno v:
Cancer immunology research. 8(6)
Antiangiogenic therapies that target the VEGF pathway have been used clinically to combat cancer for over a decade. Beyond having a direct impact on blood vessel development and tumor perfusion, accumulating evidence indicates that these agents also
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::60dc0eae081c1809b207fa41161dda9b
https://pubmed.ncbi.nlm.nih.gov/32238381
https://pubmed.ncbi.nlm.nih.gov/32238381
Autor:
Kevin Walsh, Melissa R. Junttila, Aurelie Herault, James Ziai, Judy Mak, Ji Li, Ryan Ybarra, Klara Totpal, Patrícia de Almeida, Teemu T. Junttila, Alfonso Arrazate
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 24(24)
Purpose: The response to cancer immune therapy is dependent on endogenous tumor-reactive T cells. To bypass this requirement, CD3-bispecific antibodies have been developed to induce a polyclonal T-cell response against the tumor. Anti-HER2/CD3 T-cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe436f2ea2ea6fa383024122e97d516f
https://pubmed.ncbi.nlm.nih.gov/29950350
https://pubmed.ncbi.nlm.nih.gov/29950350